Le Lézard
Classified in: Health, Covid-19 virus
Subject: TRI

Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMunetm Administration


OCEANSIDE, Calif., Aug. 5, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a patent on new data demonstrating memory-protective effects of QuadraMunetm in an animal model of inflammation associated memory loss. 

Animals were treated with QuadraMunetm for 3 days and exposed to lipopolysaccharide, which serves as an inflammatory stimulus.  Subsequently, the ability of animals to remember a submerged platform was assessed.  In agreement with previously published studies, lipopolysaccharide administration resulted in approximately 57% reduction in memory.  Animals which received QuadraMune had restoration of memory activity.  Additionally, it was demonstrated that QuadraMunetm reduced the presence of proteins associated with inflammation in the brain, termed cytokines.

"The current data is an extension of our ongoing obsession with identifying mechanisms by which QuadraMunetm works and expanding its potential for other diseases.  It is known that conditions such as Alzheimer's Disease, Multiple Sclerosis and Parkinson's Disease are all associated with brain inflammation [1, 2]," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The same cytokines, such as interleukin 6, that we are reducing with QuadraMunetm in the brain, are associated with COVID-19 severity [3].  Studies show that viral infections in general, and especially the SARS-CoV-2 virus, can cause memory impairment.  It will be interesting to explore whether QuadraMunetm may have therapeutic effects in this arena."

QuadraMunetm is comprised of green tea extract, pterostilbene, nigella sativa, and sulforaphane.  Studies published in the peer-reviewed literature have shown that these ingredients by themselves possess anti-inflammatory [4-7], neuroprotective [8-13], and immune stimulatory properties [14-17].

"It has not escaped us that mental health issues such as dementia and depression are associated with inflammatory cytokines [18, 19].  We are currently investigating the possibility of utilizing QuadraMunetm or similar formulations for psychiatric indications," said Famela Ramos, director of business development and co-inventor on the patent.

"I am very thankful for our scientific advisory board, and our research collaborators who are working tirelessly to advance QuadraMunetm into new indications, as well as identifying mechanisms of action," said Timothy Dixon, President and CEO of the Company. "We plan to continue expanding our collaborations and strengthening our science and portfolio, because at the end of the day, the best marketing is when the science speaks for itself."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com , our public forum where all are welcome is https://board.therapeuticsolutionsint.com/ and all referenced lit may be reviewed here: https://therapeuticsolutionsint.com/news-8-5-2020-refrences/

Therapeutic Solutions International, Inc.
[email protected]

SOURCE Therapeutic Solutions International


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: